Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

This study has been completed.
Information provided by (Responsible Party):
HealthPartners Institute Identifier:
First received: September 16, 2011
Last updated: September 25, 2015
Last verified: September 2015
The purpose of this study is to investigate the effect of the rapidly acting intranasal insulin derivative (glulisine) on memory and cognition in 12 patients suffering from mild-moderate Alzheimer's Disease (AD) using a double-blind placebo-controlled single dose study. This study will further assess safety of insulin glulisine as well as the effects of this drug on olfaction.

Condition Intervention Phase
Alzheimer's Disease
Drug: Insulin glulisine
Drug: Saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.

Resource links provided by NLM:

Further study details as provided by HealthPartners Institute:

Primary Outcome Measures:
  • Cognitive Performance [ Time Frame: 20 minutes post-intranasal administration ]

    The results are presented as a mean number of correct responses for each cognitive assessment.

    For each of these, a lower number correct is indicative of a higher cognitive deficit.

    Ranges are as follows: RBANS List Learning (0-40), RBANS Story Memory (0-24), RBANS Figure Copy (0-20), RBANSLine Orientation (0-20), RBANS Semantic Fluency (0-unlimited), RBANS List Recall (0-10), RBANS List Recognition (0-20), RBANS Story Recall (0-12), RBANS Figure Recall (0-20), Digit Span Forward (0-16), Digit Span Backward (0-16), Boston Naming (0-15).

  • Trails B - Seconds [ Time Frame: 20 minutes post-intranasal administration ]
    The results are presented as the number of seconds to complete Trails B. For each of these, a higher number of seconds is indicative of a higher cognitive deficit.

  • Trails B - Errors [ Time Frame: 20 minutes post-intranasal administration ]
    The results are presented as the mean sum of the errors during the Trails B assessment For each of these, a higher number of errors is indicative of a higher cognitive deficit.

Secondary Outcome Measures:
  • Olfactory Function [ Time Frame: 60 minute post intranasal administration ]

    The Sniff Magnitude Test (SMT) measures olfactory function not influenced by cognitive problems (minimal dependence on language, cognitive ability, memory, and odor naming ability). Sniff magnitude ratios are calculated as a ratio of sniff magnitudes (area under the sniff curve). Lower sniff magnitude ratios indicate more impairment.

    [average sniff magnitude of malodor/average sniff magnitude to a null odor]

Enrollment: 12
Study Start Date: September 2011
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Insulin glulisine
A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
Drug: Insulin glulisine
Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
Other Name: Apidra
Placebo Comparator: Saline
A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
Drug: Saline
Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
Other Name: salt water

Detailed Description:
A single center, phase II randomized, double-blind, placebo-controlled, cross-over study designed to assess the efficacy and safety of intranasally (IN) delivered insulin glulisine versus placebo in patients aged 65-85 with mild-moderate Alzheimer's Disease (AD). Twelve AD subjects (six female and six male) will be randomized to receive a single dose of either 20 IU/IN insulin glulisine or placebo using the MAD 300 device.

Ages Eligible for Study:   65 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject with a clinical diagnosis of probable AD in accordance with National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and Dementia Rating Scale (McKhann 1984).
  • Mini-Mental State Examination (MMSE) score of 18-26.
  • Hachinski Ischemia Score < 4.
  • Age is > 65 and <85 years
  • Females must be > 2 years post-menopausal or surgically sterile.
  • Must be able to speak, read and understand English in order to comply with testing of cognitive function, memory and physiology.
  • Must have a dedicated family member /caregiver, able to attend all visits and report on subject's status.
  • Subject and family member/caregiver have both provided fully informed written consent prior to participation. In the event that subject is legally unable to provide informed written consent due to deterioration in cognitive abilities, fully informed written consent must be provided by a legally authorized representative.
  • On a stable dose (≥ 1 months) of a prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) and/or memantine.
  • A brain CT or MRI in the last 2 years compatible with the diagnosis of probable Alzheimer's Disease.
  • A Clinical Dementia Rating (CDR) ranging from 1 to 2.

Exclusion Criteria:

  • Medical history and/or clinically determined evidence of other central nervous system (CNS) disorders including brain tumor, active subdural hematoma, seizure disorder, multiple sclerosis dementia with Lewy bodies, vascular dementia, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease, multiple system atrophy, frontotemporal dementia, normal pressure hydrocephalus, Huntington's disease, or Jakob-Creutzfeldt disease presenting as dementia.
  • Personal medical history and/or clinically determined disorders: current B12 deficiency, positive syphilis serology, chronic sinusitis or any untreated thyroid disease, significant head trauma, or history of difficulty with smell and/or taste prior to AD diagnosis.
  • Diagnosis with any form of diabetes mellitus, actively takes insulin, or has HbA1c > 6.1 % at screening.
  • Personal history of any of the following: moderate to severe pulmonary disease, congestive heart failure, significant cardiovascular and/or cerebrovascular events in previous 6 months, condition known to affect absorption, distribution, metabolism, or excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by Investigator.
  • Heavy smoker (defined as smoking half a pack or more per day in the last 10 years prior to entry in the study).
  • Personal history of any psychiatric illness, except major depressive disorder (according to Diagnostic and Statistical Manual (DSM)-IV TR) currently in remission or stable with treatment for > 2 years, or any other psychiatric condition that inclusion would pose a safety risk to the subject as determined by Investigator. Patients with active depression (Geriatric Depression Score>9) are excluded from the study.
  • Currently taking any medications, herbals and food supplements that are determined by Investigator to interfere with procedural testing of cognitive function as well as ensure study safety.
  • Recent change (< 1 months) in prescribed acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) or memantine.
  • Current or recent drug or alcohol abuse or dependence defined by DSM-IV TR.
  • Systolic blood pressure > 160 or < 90 mmHg or diastolic blood pressure > 100 or < 60 mmHg at Screening.
  • Screening laboratory results that are medically relevant and which would pose a safety risk to the subject as determined by Investigator.
  • Participation in any other research study at least 3 months prior to this study.
  • Insulin allergy.
  • History of significant traumatic brain injury
  • History of acute and chronic rhinitis and/or sinusitis.
  • Legally unable to provide informed written consent due to deterioration in cognitive abilities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01436045

United States, Minnesota
HealthPartners Specialty Center - Center for Dementia & Alzheimer's Care
St. Paul, Minnesota, United States, 55130
Sponsors and Collaborators
HealthPartners Institute
Principal Investigator: Michael H Rosenbloom, MD HealthPartners Institute
  More Information

Responsible Party: HealthPartners Institute Identifier: NCT01436045     History of Changes
Other Study ID Numbers: 11-111
Study First Received: September 16, 2011
Results First Received: April 9, 2015
Last Updated: September 25, 2015

Keywords provided by HealthPartners Institute:
Insulin glulisine
Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Insulin, Globin Zinc
Insulin glulisine
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 25, 2017